Opendata, web and dolomites

TRIPLECON

Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRIPLECON project word cloud

Explore the words cloud of the TRIPLECON project. It provides you a very rough idea of what is the project "TRIPLECON" about.

owing    combination    her2    strikingly    unsatisfactory    disproportionally    preliminary    attempted    approved    benefiting    cytotoxic    er    dual    patient    revealed    mouse    proof    drug    treat    combinatorial    overexpressed    agent    signaling    clinical    receptor    pr    successful    compensatory    models    striving    family    aggressive    grant    giving    trials    treatment    clinic    death    intrinsic    forms    triple    chemotherapies    cdk9    vivo    ongoing    erc    inhibit    single    lines    concomitantly    bc    cancer    lapatinib    causing    pharmacological    benefit    express    synergistic    accounting    synergized    pdx    safe    20    resistance    epidermal    therapies    block    negative    envisage    tnbc    disease    clinically    mainstay    targetable    strategy    instance    15    cell    translate    molecular    dysregulated    proliferation    xenograft    kinase    322737    poor    poc    inhibitor    therapy    explore    outcomes    cyclin    stalling    breast    80    patients    egfr    dependent    receptors    drive   

Project "TRIPLECON" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 90˙075.00
2    UNIVERSITEIT LEIDEN NL (LEIDEN) participant 59˙925.00

Map

 Project objective

'Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer. Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies. Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance. Clinical trials have attempted to explore molecular targeted therapies to block dysregulated growth factor receptors in TNBC, for instance, epidermal growth factor receptor (EGFR), as it is overexpressed in ~80% of TNBC. Yet, giving the long-standing availability of clinically approved EGFR-targeted therapies, such as lapatinib, the clinical benefit of single agent therapy is unsatisfactory, owing to the compensatory dysregulated signaling pathways. In our ongoing ERC – Advanced Grant Triple-BC (#322737) we are striving to explore combinatorial molecular targeted therapies to concomitantly block the identified dysregulated signaling pathways. Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergized with targeting EGFR receptor family signaling to inhibit cell proliferation of TNBC cell lines. The overall goal of this PoC project is to exploit this novel finding and provide proof-of-concept evidence that stalling CDK9 signaling may enable successful targeted combination therapy in TNBC. Therefore, the specific objective is to assess the pharmacological response of dual EGFR-CDK9 targeting in TNBC patient-derived xenograft (PDX) mouse models in vivo. We envisage that this PoC project will translate our identified successful synergistic treatment into an effective future novel and safe combinatorial targeting strategy benefiting TNBC patients.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIPLECON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIPLECON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More